Astra Moves to Profit From Covid Shot as Earnings Fall Short
- Drugmaker pledged not to profit on vaccine during pandemic
- Shares fall after quarterly earnings miss analyst estimates
Boxes of AstraZeneca's Covid-19 vaccines.
Photographer: Remko de Waal/AFP/Getty ImagesThis article is for subscribers only.
Sign up here for our daily coronavirus newsletter on what you need to know
AstraZeneca Plc is moving to profit from the Covid-19 vaccine it developed with the University of Oxford after watching Pfizer Inc. and Moderna Inc. reap huge returns over the past year of the pandemic.